Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
暂无分享,去创建一个
C. Huff | Richard J. Jones | B. Smith | J. Bolaños-Meade | J. Powell | L. Swinnen | Y. Kasamon | R. Brodsky | W. Matsui | R. Ambinder | L. Luznik | E. Fuchs | R. Jones | M. Levy | R. Brodsky | J. Bolaños-Meade | M. Muth
[1] Allen R. Chen,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Ayas,et al. Second stem cell transplantation in patients with Fanconi anemia using antithymocyte globulin alone for conditioning. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] K. Sullivan,et al. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection , 2008, Bone Marrow Transplantation.
[4] M. Perales,et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] D. Jacobsohn,et al. Acute graft-versus-host disease. , 1990, Cancer treatment and research.
[6] E. Jabbour,et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation , 2007, Bone Marrow Transplantation.
[7] Allen R. Chen,et al. 6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT) , 2007 .
[8] C. R. Allen,et al. Post-Transplantation High-Dose Cyclophosphamide (Cy) Is Effective Single Agent GVHD Prophylaxis That Permits Prompt Immune Reconstitution after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). , 2006 .
[9] M. Hallek,et al. Fludarabine in chronic lymphocytic leukaemia , 2006, Expert opinion on pharmacotherapy.
[10] A. Felten,et al. Successful allogeneic bone marrow retransplantation with the same donor after graft rejection: Application of a modified conditioning regimen , 1979, Blut.
[11] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] M. Aljurf,et al. Second Allogeneic Bone Marrow Transplantation after Myeloablative Conditioning Analysis of 43 Cases from Single Institution , 2004, Hematology.
[13] J. Bolaños-Meade,et al. Acute graft-versus-host disease. , 2004, Clinical advances in hematology & oncology : H&O.
[14] R. Storb,et al. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). , 1998, Blood.
[15] C Anasetti,et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.
[16] J. Cornish,et al. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation , 1998, Bone Marrow Transplantation.
[17] H. Holland,et al. Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions , 1997, Bone Marrow Transplantation.
[18] H. Deeg,et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. , 1996, Transplantation.
[19] H. Deeg,et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.
[20] J. Radich,et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Piantadosi,et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Rimm,et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. , 1989, Blood.
[23] K. Sullivan,et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.
[24] K. Sullivan,et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. , 1987, Blood.
[25] R. Brookmeyer,et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.
[26] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.
[27] A. Britten,et al. Successful retransplantation of bone marrow following failure of initial engraftment in a patient with aplastic anemia. , 1976, Jornal de Pediatria.
[28] Bone marrow transplantation from donors with aplastic anemia. A report from the ACS/NIH bone marrow transplant registry. , 1976, JAMA.
[29] J. Kersey,et al. RETRANSPLANTATION OF HUMAN BONE MARROW: Two IMMUNOSUPPRESSIVE DRUG REGIMENS , 1975, Transplantation.